L 345

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596524

CAS#: 121809-82-3

Description: L 345 is a bioactive chemical.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-01-28. Prices are subject to change without notice.

L 345 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 596524
Name: L 345
CAS#: 121809-82-3
Chemical Formula: C17H15Cl3N2O4
Exact Mass: 416.0097
Molecular Weight: 417.66
Elemental Analysis: C, 48.89; H, 3.62; Cl, 25.46; N, 6.71; O, 15.32

Synonym: L 345; L-345; L345;

IUPAC/Chemical Name: 2-methyl-2-(4-(3-(3,4,5-trichlorophenyl)ureido)phenoxy)propanoic acid


InChi Code: InChI=1S/C17H15Cl3N2O4/c1-17(2,15(23)24)26-11-5-3-9(4-6-11)21-16(25)22-10-7-12(18)14(20)13(19)8-10/h3-8H,1-2H3,(H,23,24)(H2,21,22,25)

SMILES Code: CC(OC1=CC=C(NC(NC2=CC(Cl)=C(Cl)C(Cl)=C2)=O)C=C1)(C)C(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Horjen AW, Seljeflot I, Berge T, Smith P, Arnesen H, Tveit A. Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation. Thromb J. 2017 Dec 28;15:30. doi: 10.1186/s12959-017-0153-1. eCollection 2017. PubMed PMID: 29299030; PubMed Central PMCID: PMC5745972.

2: Riddle MC. Diabetes: Controlling glucose levels in elderly people--benefits versus risks. Nat Rev Endocrinol. 2015 May;11(5):257-8. doi: 10.1038/nrendo.2015.23. Epub 2015 Feb 24. PubMed PMID: 25707784.

3: Bi XY, Zhao JJ, Yan T, Li C, Zhou HT, Huang Z, Zhao H, Cai JQ. [Peri-operative treatment for hepatocellular carcinoma patients complied with cirrhosis and hypersplenism]. Zhonghua Wai Ke Za Zhi. 2010 Oct 15;48(20):1539-41. Chinese. PubMed PMID: 21176666.

4: Riddle MC. Therapy: What evidence should guide the use of thiazolidinediones? Nat Rev Endocrinol. 2010 Nov;6(11):600-2. doi: 10.1038/nrendo.2010.156. PubMed PMID: 20962864.

5: Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010 Aug 24;122(8):844-6. doi: 10.1161/CIRCULATIONAHA.110.960138. PubMed PMID: 20733112; PubMed Central PMCID: PMC2980502.

6: Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care. 2008 Feb;31 Suppl 2:S125-30. doi: 10.2337/dc08-s231. PubMed PMID: 18227472.

7: Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab. 2008 Feb;93(2):372-4. Epub 2007 Dec 11. PubMed PMID: 18073293.

8: Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998 Jul;21(7):1052-7. PubMed PMID: 9653594.

9: Kister J, Griffon N, Henthorn JS, Marden MC, Poyart C, Papassotiriou I, Promé D, Galactéros F, Davies SC, Wajcman H. Alteration of an intersubunit contact in hemoglobin variants: comparative study of modifications at position alpha 126 Asp (H9). C R Acad Sci III. 1997 Nov;320(11):849-55. PubMed PMID: 9499936.

10: Dumoulin A, Kiger L, Jiang R, Baudin V, Vasseur C, Sligar SG, Marden MC, Pagnier J, Poyart C. Loss of allosteric behaviour in recombinant hemoglobin alpha 2 beta 2(92)(F8) His-->Ala: restoration upon addition of strong effectors. FEBS Lett. 1995 Oct 23;374(1):39-42. PubMed PMID: 7589508.

11: Yamamoto J, Ohyanagi M, Morita M, Iwasaki T. Beta-adrenoceptor-G protein-adenylate cyclase complex in rat hearts with ischemic heart failure produced by coronary artery ligation. J Mol Cell Cardiol. 1994 May;26(5):617-26. PubMed PMID: 8072016.

12: Lalezari I, Lalezari P, Poyart C, Marden M, Kister J, Bohn B, Fermi G, Perutz MF. New effectors of human hemoglobin: structure and function. Biochemistry. 1990 Feb 13;29(6):1515-23. PubMed PMID: 2334712.

13: Langner NR, Hasselback PD, Dunkley GC, Corber SJ. Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels. CMAJ. 1989 Jul 1;141(1):33-8. Erratum in: Can Med Assoc J 1989 Aug 15;141(4):278. PubMed PMID: 2731100; PubMed Central PMCID: PMC1269270.